Lead Product(s): Doxycycline Monohydrate
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Aurum Ventures
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 24, 2020
The proceeds from the round would be used to finance advanced clinical development of its leading product, D-Plex100.